Earnings reports

Nikos Pekiaridis | Nurphoto | Getty ImagesModerna on Thursday posted a surprise quarterly profit, in part boosted by deferred revenue, even as the company saw slumping sales from its Covid vaccine, its only marketable product. The results cap a rocky year for the biotech company and other Covid vaccine makers, which all saw revenue plunge as the world continued to emerge from pandemic and relied less on protective shots and treatments.Here's what Moderna reported for the fourth quarter compared with what Wall Street was…

DoorDash stock hit a 52-week high Thursday, but quickly fell from that peak in after-hours trading as investors digested the company’s fourth-quarter earnings.The delivery company reported a 39-cent-per-share loss, compared to analyst expectations of just 16 cents. That sent shares down more than 9.5% in the post-market at one point. The company, however, attempted to shift investor focus to the overall adjusted EBITA (earnings before interest, taxes and amortization). That number beat expectations of $356 million, coming…

Pfizer on Tuesday posted a surprise adjusted fourth-quarter profit, as the company's declining Covid business performed better than expected.The company reversed roughly $3.5 billion in revenue related to the expected return of 6.5 million doses of its Covid drug, Paxlovid, from the U.S. government. That hit is less than the $4.2 billion Pfizer initially expected for the return of nearly 8 million doses of Paxlovid.Pfizer's Covid vaccine raked in $5.36 billion in revenue for the quarter, down 53% from the same period last…